X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Zokinvy (lonafarnib) is a first-in-class farnesyltransferase inhibitor. It is approved for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Eiger BioPharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
Under the terms of the agreement, AnGes is responsible for obtaining and maintaining regulatory approval for Zokinvy (lonafarnib) in Japan and will be the exclusive partner for distribution and commercialization.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Eiger BioPharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 10, 2022
Details:
EmendoBio to operate as an independent subsidiary of AnGes with full access to AnGes’ global development resources to accelerate development and manufacturing capabilities for EmendoBio’s dual OMNI™ genome editing technology platforms.
Lead Product(s): EMD-101
Therapeutic Area: Genetic Disease Product Name: EMD-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Emendo Biotherapeutics
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 15, 2020
Details:
The trials involve 500 people. A group of 250 people will be vaccinated twice with AG0302-COVID19, in an interval of two weeks; the second group of 250 people twice with an interval of four weeks.
Lead Product(s): AG0302-COVID19
Therapeutic Area: Infections and Infectious Diseases Product Name: AG0302-COVID19
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
Under the terms of the agreement, Er-Kim will have the exclusive rights to commercialize Collategene® in Turkey after obtaining the necessary regulatory approvals.
Lead Product(s): Beperminogene Perplasmid
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Collategene
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Er-Kim
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 08, 2020
Details:
AnGes is currently conducting Phase 1/2 clinical studies with its vaccine candidate in Japan, and the results from these studies will guide AnGes’ and Brickell’s global development efforts of this novel vaccine candidate.
Lead Product(s): AG0302-COVID19
Therapeutic Area: Infections and Infectious Diseases Product Name: AG0302-COVID19
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Fresh Tracks Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 08, 2020
Details:
The company is working on the developement of a prophylactic DNA vaccine for COVID-19 using plasmid DNA production technology.
Lead Product(s): DNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2020
Details:
The funding will accelerate novel OMNI gene editing platform into a broad therapeutic product pipeline.
Lead Product(s): OMNI nuclease
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Emendo Biotherapeutics
Deal Size: $61.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
